Stringent Disease Activity Control at 2 Years Across Psoriatic Arthritis Domains Irrespective of Baseline Characteristics in Patients Treated with Guselkumab: Post-Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study

被引：0
|
作者：
Ritchlin, Christopher T. [1 ]
Mease, Philip J. [2 ,3 ]
Boehncke, Wolf-Henning [4 ]
Tesser, John [5 ]
Chakravarty, Soumya D. [6 ,7 ]
Rampakakis, Emmanouil [8 ,9 ]
Shawi, May [10 ]
Merola, Joseph F. [11 ]
McInnes, Iain B. [12 ]
Deodhar, Atul [13 ]
机构：
[1] Univ Rochester, Med Ctr, Rochester, NY USA
[2] Swedish Med Ctr, Providence St Joseph Hlth, Seattle, WA USA
[3] Univ Washington, Seattle, WA USA
[4] Univ Geneva, Univ Hosp Geneva, Div Dermatol, Geneva, Switzerland
[5] Arizona Arthrit & Rheumatol Associates, Phoenix, AZ USA
[6] Janssen Sci Affairs LLC, Horsham, PA USA
[7] Drexel Univ, Coll Med, Philadelphia, PA USA
[8] McGill Univ, Dept Pediat, Montreal, PQ, Canada
[9] JSS Med Res Inc, Montreal, PQ, Canada
[10] Johnson & Johnson, Janssen Pharmaceut Co, Immunol Global Med Affairs, Horsham, PA USA
[11] Harvard Med Sch, Brigham & Womens Hosp, Div Rheumatol & Immunol, Boston, MA USA
[12] Univ Glasgow, Coll Med Vet & Life Sci, Glasgow, Scotland
[13] Oregon Hlth & Sci Univ, Div Arthrit & Rheumat Dis, Portland, OR USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
42148
引用
收藏
页码：AB225 / AB225
页数：1
相关论文
共 50 条
  • [31] Efficacy and Safety Results of Guselkumab in Patients with Active Psoriatic Arthritis over 56 Weeks from a Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study
    Deodhar, Atul A.
    Gottlieb, Alice B.
    Boehncke, Wolf-Henning
    Dong, Bin
    Wang, Yuhua
    Zhuang, Yanli
    Barchuk, William
    Xu, Xie L.
    Hsia, Elizabeth
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [32] Achievement of Low Disease Activity/Remission in Guselkumab-Treated Patients with Moderately-Highly Active Psoriatic Arthritis Regardless of Baseline Characteristics: Pooled Post-Hoc Analysis of Two Phase 3/Randomized Studies
    Mease, Philip
    Gottlieb, Alice
    McInnes, Iain
    Shiff, Natalie J.
    Todd, Anthony
    Rampakakis, Emmanouil
    Nantel, Francois
    Parrett, Jenna
    Lavie, Frederic
    Rahman, Proton
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 2993 - 2996
  • [33] Guselkumab Shows Similar Domain-Specific Efficacy in Females and Males with Active Psoriatic Arthritis: Post Hoc Analyses of Three Phase 3, Randomized, Double-blind, Placebo-Controlled Studies
    Eder, Lihi
    Selmi, Carlo
    Mease, Philip
    Ogdie, Alexis
    Nantel, Francois
    Lavie, Frederic
    Sharaf, Mohamed
    Adelakun, Oyediran
    Rampakakis, Emmanouil
    Vegas, Laura Pina
    Coates, Laura
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 4720 - 4722
  • [34] Long-term Efficacy of Guselkumab (GUS) on Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-blind, Placebo-controlled Study in Biologic-na_ive Patients With Psoriatic Arthritis (PsA)
    Gladman, Dafna D.
    Starr, Michael
    Ranza, Roberto
    Bravo, Ana-Maria
    Strauss, Marcie
    Shawi, May
    Han, Chenglong
    Rampakakis, Emmanouil
    Ostor, Andrew
    Mease, Philip J.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB189 - AB189
  • [35] Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 Trials
    Philip Mease
    Arthur Kavanaugh
    Dafna Gladman
    Oliver FitzGerald
    Enrique R. Soriano
    Peter Nash
    Dai Feng
    Apinya Lertratanakul
    Kevin Douglas
    Ralph Lippe
    Laure Gossec
    Rheumatology and Therapy, 2022, 9 : 1181 - 1191
  • [36] Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 Trials
    Mease, Philip
    Kavanaugh, Arthur
    Gladman, Dafna
    FitzGerald, Oliver
    Soriano, Enrique R.
    Nash, Peter
    Feng, Dai
    Lertratanakul, Apinya
    Douglas, Kevin
    Lippe, Ralph
    Gossec, Laure
    RHEUMATOLOGY AND THERAPY, 2022, 9 (04) : 1181 - 1191
  • [37] Impact of Galcanezumab on Total Pain Burden in Patients With Chronic Cluster Headache: Post-hoc Analysis From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
    Kudrow, D.
    Kuruppu, D.
    Andrews, J.
    Rettiganti, M.
    Oakes, T. M.
    Bardos, J.
    Wenzel, R.
    Gaul, C.
    Martinez, J.
    Lipton, R. B.
    HEADACHE, 2020, 60 : 108 - 109
  • [38] Efficacy of novel β3-adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: A post-hoc analysis of a randomized, double-blind, placebo-controlled phase 3 study
    Yoshida, Masaki
    Takeda, Masayuki
    Gotoh, Momokazu
    Yokoyama, Osamu
    Kakizaki, Hidehiro
    Takahashi, Satoru
    Masumori, Naoya
    Nagai, Shinji
    Hashimoto, Keita
    Minemura, Kazuyoshi
    INTERNATIONAL JOURNAL OF UROLOGY, 2019, 26 (03) : 369 - 375
  • [39] Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial
    Mease, Philip J.
    Rahman, Proton
    Gottlieb, Alice B.
    Kollmeier, Alexa P.
    Hsia, Elizabeth C.
    Xu, Xie L.
    Sheng, Shihong
    Agarwal, Prasheen
    Zhou, Bei
    Zhuang, Yanli
    van der Heijde, Desiree
    McInnes, Iain B.
    LANCET, 2020, 395 (10230): : 1126 - 1136
  • [40] GUSELKUMAB EFFICACY IN ADULT PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS BY BASELINE DEMOGRAPHIC AND DISEASE CHARACTERISTICS: POOLED RESULTS OF TWO PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDIES
    Deodhar, Atul
    Mease, Philip J.
    Boencke, Wolf-Henning
    Tesser, John
    Schiopu, Elena
    Chakravarty, Soumya D.
    Kollmeier, Alexa P.
    Hsia, Elizabeth C.
    Xu, Xie L.
    Shawi, May
    Jiang, Yusang
    Sheng, Shihong
    Agarwal, Prasheen
    Merola, Joseph F.
    McInnes, Iain B.
    Ritchlin, Christopher T.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2021, 27 : S108 - S109
12345